Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Pfizer Inc.
< Previous
1
2
3
4
5
6
7
8
9
Next >
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
May 25, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19
May 25, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization
May 18, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Prices $31,000,000,000 Debt Offering
May 16, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Proposed Notes Offering
May 15, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Reports First-Quarter 2023 Results
May 02, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
April 27, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Declares Second-Quarter 2023 Dividend
April 26, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27
April 13, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
April 04, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
March 21, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
March 16, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
March 10, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
February 28, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 27, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
February 22, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review
February 21, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
February 16, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults
February 16, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
February 10, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 09, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
January 31, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries
January 17, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
January 06, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 03, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate
December 29, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
December 28, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
December 21, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts
December 20, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial
December 10, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.